All articles

Thymosin alpha-1: an immune peptide and what the studies showed

What this immune peptide is and what studies showed about it

What it is

Thymosin alpha-1 is a small protein, a signal for immunity.

  • it was first found in the thymus
  • the thymus is a gland behind the breastbone
  • the medicine uses an exact copy

Where it comes from

The thymus trains immune cells.

  • T cells mature there
  • T cells are the coordinators of immunity
  • with age the thymus gets smaller

How it works

The peptide tells cells to switch on.

  • guard cells receive the signal
  • they react more actively to a threat
  • this is how reviews describe the mechanism

How it is given

The medicine is given as a small injection under the skin.

  • the drug comes as a powder
  • it is mixed with water
  • a doctor chooses the regimen

Hepatitis

The oldest use is viral hepatitis.

  • often together with other drugs
  • results of different studies are not the same
  • today there are modern medicines too

Severe infection

In sepsis, a large study showed no difference.

  • people were compared with a placebo group
  • an important result: an honest test
  • decisions are made in the hospital

Vaccination

Alongside a vaccine, more antibodies were made.

  • small studies showed this
  • antibodies were measured, not illness
  • the authors want it tested in larger groups

Oncology

The peptide was tried as an addition to melanoma treatment.

  • a tumor response was more common
  • there was no significant difference in survival
  • the main treatment stays with the doctor

Coronavirus

In COVID-19, no clinical benefit was shown.

  • large observational studies show no difference
  • studies reached different conclusions
  • so there is no general advice

How it is tolerated

Short courses were tolerated like a placebo.

  • most often the injection site hurts
  • serious cases were no more than on placebo
  • long courses are the doctor's decision

Who should see a doctor first

There are cases when you cannot go without a doctor.

  • organ transplant and weak immunity
  • allergy to the components
  • pregnancy, breastfeeding, children
  • severe infection or hepatitis

Important. Such a drug is prescribed only by a doctor after an examination and tests.

The main point

An immune peptide with a clear mechanism.

  • the best results are in hepatitis combined with other drugs
  • in sepsis and COVID-19 there is no difference between groups
  • a doctor decides, not self-administration

Frequently asked questions

It is a peptide of 28 amino acids, first isolated from the thymus. The synthetic form is called thymalfasin (Zadaxin). According to a review, the drug is registered in more than 35 countries for hepatitis B and C and as an immune agent (Dominari A World J Virol 2020. PMID 33362999).

According to reviews, it switches on Toll-like receptors on dendritic and myeloid cells, activates dendritic cells and NK cells, helps T cells mature and raises interleukin-2 (Dominari A World J Virol 2020. PMID 33362999).

In the largest double-blind study, with 1089 people, 28-day mortality was 23.4% versus 24.1% on placebo, with no difference (Wu J BMJ 2025. PMID 39814420). In a meta-analysis of 11 studies, among the higher-quality trials the odds ratio was 0.82 (0.65–1.03) (Gu B Front Cell Infect Microbiol 2025. PMID 40969554).

In the TESTS study (1089 people, 7-day course), adverse events occurred in 66.4% and 67.6% on placebo, serious ones in 26.8% and 29.3% (Wu J BMJ 2025. PMID 39814420). It is contraindicated in hypersensitivity and in immunosuppression, including after organ transplantation, unless the benefit outweighs the risk.

In hepatitis studies, 1.6 mg under the skin twice a week, usually for 6–12 months; in sepsis, 1.6 mg twice a day for 7 days (Ancell CD Am J Health Syst Pharm 2001. PMID 11381492; Wu J BMJ 2025. PMID 39814420). The regimen is set by a doctor.

Interferon suppresses the virus directly, while thymosin raises the activity of immune cells through signals. In a comparison in hepatitis B (199 people, 4 studies), thymosin did not outperform interferon at the end of the course, and 6 months after treatment the odds ratio for a complete response was 2.69 (1.47–4.91) (Yang YF Antiviral Res 2008. PMID 18078676).

In a pilot randomized study of 49 people, clinical recovery did not differ significantly (Shehadeh F J Infect Dis 2023. PMID 36056913). Two meta-analyses disagree: risk ratio 1.03 (0.60–1.75) across 9 studies (5352 people) and 0.59 (0.37–0.93) across 8 studies.

Share
Follow on TelegramGet new articles, research updates and practical health tips
Читать на русскомЧитати українською

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician before making health decisions. Full disclaimer

Ready to Take Action?

A consultation starts where the article ends: your history, your labs, a plan for your case.

Book consultationAsk a question